31th PAGE Meeting

A Coruña - Spain
27-30 June, 2023

View abstracts

Home / 2023 – A Coruña – Spain / Abstracts

← Back to filters

Abstracts (15)

II-05Mahmoud Ali

Evaluation of the robustness of methods for model-based bioequivalence analysis for biosimilars: Clenoliximab as a case study

Wednesday 15:35-17:00

II-25Geraldine Celliere

Comparison of a typical PK/PD model versus a mechanistic QSP model to predict the Phase II of a PSCK9 inhibitor, using MonolixSuite

Wednesday 15:35-17:00

II-35Pieter-Jan De Sutter

Comparison of monoclonal antibody disposition predictions between different PBPK platforms

Wednesday 15:35-17:00

II-84Teun Post

Innovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration-based dosing, applied to a population dose-hemoglobin model for Jesduvroq (daprodustat)

Wednesday 15:35-17:00

II-85Mar Ribera I Armengol

Application of Structural Identifiability Analysis and Parametrisation of a Linear Mixed Effects Mirabegron Model

Wednesday 15:35-17:00

II-93Mohamed Tarek

Fast cross-validation for Bayesian inference using proposals on a linear subspace

Wednesday 15:35-17:00

II-95Monika Twarogowska

A method to correct VPC bias due to non-random dropout via censored data addition, using the MonolixSuite

Wednesday 15:35-17:00

II-96Martijn van Noort

Two new user-friendly approaches to assess pharmacometric model identifiability

Wednesday 15:35-17:00

IV-07Alexandre Duong

NONMEM versus nlmixr2 : An example of external evaluation of gentamicin Pop-PK models

Thursday 15:25-16:55

IV-09Mehdi El Hassani

Does sample size, sampling strategy, or handling of concentrations below the lower limit of quantification matter when externally evaluating population pharmacokinetic models?

Thursday 15:25-16:55

IV-10Selma El Messaoudi

Evaluation in model averaging: an application to viral dynamic models

Thursday 15:25-16:55

IV-11Ibrahim El-Haffaf

Model-informed precision dosing: can the administration method influence the predictive performance of a model? An example with piperacillin.

Thursday 15:25-16:55

IV-26Hyunjung Lee

External validation of population pharmacokinetic models on 7 published models of moxifloxacin-treated tuberculosis patients

Thursday 15:25-16:55

IV-34Jos Lommerse

Building Effective Visualizations to Assess and Communicate Fit for Pharmacometric Models with Covariates (VACHETTE)

Thursday 15:25-16:55

IV-40Yersultan Mirasbekov

Characterizing Bootstrap Model Selection Variability Through an Automated Model Building Approach

Thursday 15:25-16:55